Glucose-galactose malabsorption (GGM) is a rare metabolic condition. It occurs when a genetic variation makes the body unable to properly absorb the simple sugars glucose and galactose. Sugars are the ...
Breast milk is full of good things that babies need -- key nutrients, hormones, and antibodies that protect them from disease and keep them healthy. It’s easy to test for galactosemia. It’s also ...
The purpose of the present paper is to describe some observations that may help to elucidate this difference. Except where indicated all the tests were performed on the same group of 10 patients with ...
Galactose after growth: Why one early-life sugar might be overstaying its welcome, By Mukaila Kareem
There’s no conspiracy among mothers. Across all species, mothers stop producing milk when the job is done. Growth slows, and the sugar supply shuts off… Just because we can digest milk doesn’t mean we ...
A research study demonstrates in mice the biological relevance of sex in the effects of accelerated ageing caused by a chronic treatment of D-galactose, a sugar found abundantly in milk and to a ...
CAMBRIDGE, Mass., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, ...
Galactosemia is a genetic disorder in which the body cannot process galactose, which is a simple sugar that is found in many foods. It is actually part of the sugar called lactose, (lactose contains ...
Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A ...
A 41-year-old woman with congenital glucose-galactose malabsorption (CGGM) was hospitalised for hypoglycaemia, and subsequent evaluation confirmed an insulinoma. Surgical resection was successful, and ...
In our opinion the article by Van Tine et al 1 highlights the importance of testing for anti–Gal antibodies in patients who are potential candidates for treatment with mAbs, particularly cetuximab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results